BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34763504)

  • 1. Clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion and ascites caused by lung cancer: a randomized trial.
    Zhou Z; Li H; Hu D; Xie L
    Ann Palliat Med; 2021 Oct; 10(10):10575-10583. PubMed ID: 34763504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin.
    Jiang L; Li P; Gong Z; Hu B; Ma J; Wang J; Chu H; Zhang L; Sun P; Chen J
    Anticancer Res; 2016 Mar; 36(3):1313-8. PubMed ID: 26977031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
    Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
    Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites.
    Zhao WY; Chen DY; Chen JH; Ji ZN
    Cell Biochem Biophys; 2014 Sep; 70(1):623-8. PubMed ID: 24920191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
    Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
    Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
    Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
    Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.
    Xiang Z; Deng X; He W; Yang Q; Ni L; Dehghan Shasaltaneh M; Maghsoudloo M; Yang G; Wu J; Imani S; Wen Q
    Ann Med; 2022 Dec; 54(1):1357-1371. PubMed ID: 35543207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical observation on the efficacy of Xiaoshui decoction combined with intrapleural perfusion of cisplatin in treating malignant pleural effusion.
    SHI Z; HE QY; HUA BJ
    Chin J Integr Med; 2008 Dec; 14(4):257-61. PubMed ID: 19082796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer.
    Chen L; Zhu X; Li D; Cai X
    J BUON; 2020; 25(6):2643-2649. PubMed ID: 33455108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
    Nie K; Zhang Z; You Y; Zhuang X; Zhang C; Ji Y
    Thorac Cancer; 2020 Jan; 11(1):8-14. PubMed ID: 31726490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of endostar combined with cisplatin/ pemetrexed chemotherapy for elderly patients with advanced malignant pleural effusion of lung adenocarcinoma.
    Jie Wang X; Miao K; Luo Y; Li R; Shou T; Wang P; Li X
    J BUON; 2018; 23(1):92-97. PubMed ID: 29552766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effects of thermotherapy in combination with intracavitary infusion of traditional Chinese medicine in the treatment of malignant pleural effusion.
    Gu Y; Jiang L; Miao JH; Liang TS; Kan QC; Yang DK
    J Biol Regul Homeost Agents; 2016; 30(4):1023-1028. PubMed ID: 28078848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis.
    Hu Y; Zhou Z; Luo M
    Medicine (Baltimore); 2022 Dec; 101(52):e32207. PubMed ID: 36595983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
    Tamiya M; Tamiya A; Yamadori T; Nakao K; Asami K; Yasue T; Otsuka T; Shiroyama T; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Kawase I; Hirashima T
    Med Oncol; 2013; 30(3):676. PubMed ID: 23925664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion.
    Chu H; Du F; Gong Z; Lian P; Wang Z; Li P; Hu B; Chi C; Chen J
    Anticancer Res; 2017 Aug; 37(8):4587-4591. PubMed ID: 28739756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
    Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer.
    Ishida A; Miyazawa T; Miyazu Y; Iwamoto Y; Zaima M; Kanoh K; Sumiyoshi H; Doi M
    Respirology; 2006 Jan; 11(1):90-7. PubMed ID: 16423208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.